BofA revises its stance on a pair of hepatitis-C drugmakers, raising Achillion Pharma (ACHN) to...


BofA revises its stance on a pair of hepatitis-C drugmakers, raising Achillion Pharma (ACHN) to Buy and cutting Idenix Pharma (IDIX) to Neutral. The firm is more optimistic on the market potential for ACHN’s hepatitis-C drug combo, and hikes its share price target to $13 from $7. But IDIX faces difficulties after the FDA placed a clinical hold on one of its hep-C treatments. ACHN +13.5%, IDIX -5.5% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs